Slimming Pen revolution Faces Next Phase: Pills, Lifestyle Changes, and Growing Concerns
São Paulo, Brazil – The burgeoning market for obesity treatments centered around GLP-1 hormone simulating drugs like Ozempic, Wegovy, and Mounjaro is poised for a notable shift, moving beyond injectable pens toward oral medications while concurrently emphasizing the critical need for sustained lifestyle adjustments. Experts caution against viewing these drugs as standalone, permanent solutions, highlighting potential rebound effects and risks associated with unsupervised use.
The initial success of injectable GLP-1 agonists in achieving weight control and reducing related health issues like diabetes and hypertension has spurred pharmaceutical companies to invest heavily in developing tablet versions, aiming for broader accessibility. Currently, over 130 studies are in phase 3, signaling a rapid expansion of treatment options. However, challenges remain regarding cost and demonstrating long-term efficacy, alongside growing concerns about patients obtaining products without medical supervision – even through illegal channels.
Effective treatment necessitates extensive changes, including dietary re-education and increased physical activity. Professionals emphasize that obesity management requires ongoing medical,nutritional,and psychological support to mitigate the risk of weight regain after discontinuing medication. The industry’s focus is now shifting towards creating more accessible and sustainable solutions, acknowledging that pharmacological intervention is most effective when integrated with holistic lifestyle modifications.
